{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:27:53Z","timestamp":1769052473669,"version":"3.49.0"},"reference-count":23,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_hmbci-2020-0077_abs_001_w2aab3b7c48b1b6b1aab1c16b1Aa\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Prolactinoma is the most common cause of pituitary tumours. Current medical guidelines recommend dopamine agonists (cabergoline or bromocriptine) as the initial therapy for prolactinoma. However, surgical removal can also be considered in selected cases, such as patients with macroadenomas with local complications (bleeding or optic chiasm pressure) or those not responding to medical treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2020-0077_abs_002_w2aab3b7c48b1b6b1aab1c16b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The present retrospective study included patients with prolactinomas (n=43; female, 24; male, 19) who were primarily managed with medical (n=32) or surgical (n=11) treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2020-0077_abs_003_w2aab3b7c48b1b6b1aab1c16b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Macroadenoma (n=29.67%) was commonly detected in both genders (female, 54%; male, 84%). Moreover, the mean pre-treatment prolactin levels were similar in both genders (female, 683.3\u00a0\u00b1\u00a01347\u00a0ng\/mL; male, 685.4\u00a0\u00b1\u00a0805\u00a0ng\/mL; p=0.226). Surgically treated patients had a greater reduction in tumour size (27.7\u00a0\u00b1\u00a017.9\u00a0mm pre-treatment vs. 8.72\u00a0\u00b1\u00a014.2\u00a0mm post-treatment) than non-surgically treated ones (12.5\u00a0\u00b1\u00a07.5\u00a0mm pre-treatment vs. 4.1\u00a0\u00b1\u00a04.2\u00a0mm post-treatment; p=0.00). However, the decrease in prolactin levels was similar between the two patient groups (p=0.108). During the follow-up period (10.6\u00a0\u00b1\u00a07.0\u00a0years), the average cabergoline dose of the patients was 1.42\u00a0\u00b1\u00a01.47\u00a0mcg\/week.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2020-0077_abs_004_w2aab3b7c48b1b6b1aab1c16b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although a surgical approach was considered for selected cases of prolactinoma, the average dose used for medical treatment was highly inadequate for the patients in the present study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/hmbci-2020-0077","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T09:35:03Z","timestamp":1608629703000},"page":"153-157","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of surgical and\/or medical treatment in patients with prolactinomas during long-term follow-up: a retrospective single-centre study"],"prefix":"10.1515","volume":"42","author":[{"given":"Gamze","family":"Akkus","sequence":"first","affiliation":[{"name":"Division of Endocrinology , Faculty of Medicine, Cukurova University , Adana , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bar\u0131\u015f","family":"Karagun","sequence":"additional","affiliation":[{"name":"Division of Endocrinology , Faculty of Medicine, Cukurova University , Adana , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilal Nur","family":"Yald\u0131z","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine , Faculty of Medicine, Cukurova University , Adana , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehtap","family":"Evran","sequence":"additional","affiliation":[{"name":"Division of Endocrinology , Faculty of Medicine, Cukurova University , Adana , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Sert","sequence":"additional","affiliation":[{"name":"Division of Endocrinology , Faculty of Medicine, Cukurova University , Adana , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamer","family":"Tetiker","sequence":"additional","affiliation":[{"name":"Division of Endocrinology , Faculty of Medicine, Cukurova University , Adana , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"2025121207185830327_j_hmbci-2020-0077_ref_001_w2aab3b7c48b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Soto-Pedre, E, Newey, PJ, Bevan, JS, Greig, N, Leese, GP. The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the prolactin epidemiology, audit and research study (PROLEARS). Clin Endocrinol 2017;86:60\u20137.","DOI":"10.1111\/cen.13156"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_002_w2aab3b7c48b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Colao, A, Lombardi, G. Growth-hormone and prolactin excess. Lancet 1998;352:1455\u2013146.","DOI":"10.1016\/S0140-6736(98)03356-X"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_003_w2aab3b7c48b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Bahuleyan, B, Menon, G, Nair, S, Rao, BR, Easwer, HV, Krishna, K. Non-surgical management of cystic prolactinomas. J Clin Neurosci 2009;16:1421\u20134.","DOI":"10.1016\/j.jocn.2009.03.024"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_004_w2aab3b7c48b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Ciccarelli, A, Daly, AF, Beckers, A. The epidemiology of prolactinomas. Pituitary 2005;8:3\u20136.","DOI":"10.1007\/s11102-005-5079-0"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_005_w2aab3b7c48b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Primeau, V, Raftopoulos, C, Maiter, D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol 2012;166:779\u201386.","DOI":"10.1530\/EJE-11-1000"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_006_w2aab3b7c48b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Donoho, D, Edward, R. The role of surgery in the management of prolactinomas. Neurosurgery J 2019;30:509\u201314.","DOI":"10.1016\/j.nec.2019.05.010"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_007_w2aab3b7c48b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Qu, X, Wang, M, Wang, G, Han, T, Mou, C, Han, L, et al.. Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. Eur J Endocrinol 2011;164:499\u2013504.","DOI":"10.1530\/EJE-10-0961"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_008_w2aab3b7c48b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Melmed, S, Casanueva, F, Hoffman, A, Kelinberg, D, Montori, V, Schlechte, J, et al.. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273\u201388.","DOI":"10.1210\/jc.2010-1692"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_009_w2aab3b7c48b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Glezer, A, Bronstein, MD. Prolactinomas. Endocrinol Metab Clin N Am 2015;44:71\u20138.","DOI":"10.1016\/j.ecl.2014.11.003"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_010_w2aab3b7c48b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Colao, A, Sarno, AD, Cappabianca, P, Briganti, F, Pivonello, R, Di Somma, C, et al.. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003;148:325\u201331.","DOI":"10.1530\/eje.0.1480325"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_011_w2aab3b7c48b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Delgrange, E, Trouillas, J, Maiter, D, Donckier, E, Tourniaire, J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 1997;82:2102\u20137.","DOI":"10.1210\/jc.82.7.2102"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_012_w2aab3b7c48b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Vilar, L, Abucham, J, Albuquerque, JL, Araujo, LA, Azevedo, MF, Boguszewski, CL, et al.. Controversial issues in the management of hyperprolactinemia and prolactinomas- an overview by the neuroendocrinology department of the Brazilian society of endocrinology and metabolism. Arch Endocrinol Metab 2018;62:236\u201363.","DOI":"10.20945\/2359-3997000000032"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_013_w2aab3b7c48b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"\u010ces\u00e1k, T, Poczos, P, Adamkov, J, N\u00e1hlovsk\u00fd, J, Ka\u0161parov\u00e1, P, Gabalec, F, et al.. Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review. Pituitary 2018;21:561\u201370.","DOI":"10.1007\/s11102-018-0907-1"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_014_w2aab3b7c48b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Tampourlou, M, Trifanescu, R, Paluzzi, A, Ahmed, SK, Karavitaki, N. Therapy OF endocrine disease: surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur J Endocrinol 2016;175:89\u201396.","DOI":"10.1530\/EJE-16-0087"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_015_w2aab3b7c48b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Colao, A, Di Sarno, A, Landi, ML, Scavuzzo, F, Cappabianco, P, Rivanello, R, et al.. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000;85:2247\u201352.","DOI":"10.1210\/jc.85.6.2247"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_016_w2aab3b7c48b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Breil, T, Lorz, C, Choukail, D, Mitnacht, J, Inta, I, Klose, D, et al.. Clinical features and response to treatment of prolactinomas in children and adolescents: a retrospective single-centre analysis and review of the literature. Horm Res Paadiatr 2018;89:65\u2013157.","DOI":"10.1159\/000486280"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_017_w2aab3b7c48b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Vilar, L, Freitas, MC, Naves, LA, Casulari, LA, Azevedo, M, Montenegro, RJr, et al.. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest 2008;31:436\u201344.","DOI":"10.1007\/BF03346388"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_018_w2aab3b7c48b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Gillam, MP, Molitch, ME, Lombardi, G, Colao, A. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485\u2013534.","DOI":"10.1210\/er.2005-9998"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_019_w2aab3b7c48b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Wass, JA. When to discontinue treatment of prolactinoma? Nat Clin Pract Endocrinol Metabol 2006;2:298\u20139.","DOI":"10.1038\/ncpendmet0162"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_020_w2aab3b7c48b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Di Sarno, A, Londi, ML, Cappabianco, P, Salle, F, Rossi, F, Rivonello, R, et al.. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001;86:5256\u201361.","DOI":"10.1210\/jc.86.11.5256"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_021_w2aab3b7c48b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Catli, G, Abaci, A, Altincik, A, Demir, K, Can, S, Buyukgebiz, A, et al.. Hyperprolactinemia in children: clinical features and long-term results. J Pediatr Endocrinol Metab 2012;25:1123\u20138.","DOI":"10.1515\/jpem-2012-0130"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_022_w2aab3b7c48b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Bloomgarden, E, Molitch, ME. Surgical treatment of prolactinomas: cons. Endocrine 2014;47:730\u20133.","DOI":"10.1007\/s12020-014-0369-9"},{"key":"2025121207185830327_j_hmbci-2020-0077_ref_023_w2aab3b7c48b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Hamilton, DK, Vance, ML, Roulos, PT, Laws, ER. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 2005;8:53\u201360.","DOI":"10.1007\/s11102-005-5086-1"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/hmbci\/ahead-of-print\/article-10.1515-hmbci-2020-0077\/article-10.1515-hmbci-2020-0077.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2020-0077\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2020-0077\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:10:55Z","timestamp":1765527055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2020-0077\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1,27]]},"published-print":{"date-parts":[[2021,7,20]]}},"alternative-id":["10.1515\/hmbci-2020-0077"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2020-0077","relation":{},"ISSN":["1868-1891","1868-1883"],"issn-type":[{"value":"1868-1891","type":"electronic"},{"value":"1868-1883","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,17]]}}}